Loading patent…
AssigneeThe First Hospital of China Medical University
InventorsGuoxin LIANG, Hong SHANG
Estimating the term…
Biomarker of HIV or SIV infected cells and its application are provided. The marker is PLK (polo-like kinase). By inhibiting the activity of a PLK protein or clearing the same, the purpose of releasing viruses without activating a repository is achieved, such that the viruses can be detected in a physiological state and can also be recognized and cleared by an immune system or a drug in vivo. Enhancing the activity of the PLK protein directly inhibits the release of viruses in an HIV and/or SIV-infected cell. The present invention provides a new target for diagnosis and antiviral therapy of HIV and/or SIV infection, provides medication basis and guarantee for the early rapid detection and extremely early treatment of virus infection, and has important clinical value.
1-12. (canceled)
An application of a reagent for detecting a PLK3 protein in a preparation of a product for detecting an HIV-infected cell, wherein the PLK3 protein is a PLK3-201 protein, and the PLK3-201 protein has the amino acid sequence shown in SEQ ID NO:
An application of a substance capable of inhibiting an activity of a PLK3 protein in a preparation of a product for detecting and clearing an HIV-infected cell, wherein the PLK3 protein is a PLK3-201 protein, and the PLK3-201 protein has the amino acid sequence shown in SEQ ID NO:
An application of a substance capable of inhibiting an activity of a PLK3 protein in a preparation of a product for detecting an HIV-infected cell, wherein the product comprises enabling the HIV-infected cell to release detectable progeny viruses by inhibiting the activity of the PLK3 protein in the HIV-infected cell, so as to achieve a purpose of detecting the HIV-infected cell, wherein the PLK3 protein is a PLK3-201 protein, and the PLK3-201 protein has the amino acid sequence shown in SEQ ID NO:
An application of a substance capable of inhibiting an activity of a PLK3 protein in a preparation of a product for clearing an HIV-infected cell, wherein the product comprises enabling the HIV-infected cell to release progeny viruses by inhibiting the activity of the PLK3 protein in the HIV-infected cell, and then specifically recognizing the progeny viruses by a human immune system especially using CD8+T killer cells as main effector cells or recognizing the progeny viruses by a related antiviral drug, so as to achieve a purpose of clearing the HIV-infected cell;
An application of a reagent capable of enhancing an expression of a PLK3 protein in a preparation of an anti-HIV product, wherein the anti-HIV product directly inhibits a release of viruses in an HIV-infected cell by enhancing the expression of the PLK3 protein;
Dependencies are inferred from the claim text.